ENERGI-F703 for Diabetic Foot Ulcers Phase II Study

Phase 2

Completed

• Conditions: Diabetic Foot; Foot Ulcer; Diabetes Mellitus; Wounds
• Interventions: Drug: ENERGI-F703; Drug: ENERGI-F703 matched vehicle

• Registration Number: NCT02672436
• Lead Sponsor: Energenesis Biomedical Co., Ltd.

Brief Summary

The objective of this study is to evaluate the efficacy and safety of ENERGI-F703 in subject with diabetic foot ulcers.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2016-01-27
• Study First Submitted QC: 2016-02-01
• Study First Posted: 2016-02-03
• Study Start: 2017-03-15
• Primary Completion: 2019-10-03
• Study Completion: 2019-12-26
• Status Verified: 2020-11
• Last Update Submitted: 2020-11-23
• Last Update Posted: 2020-11-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 141

Inclusion Criteria

1. With either gender aged at least 20 years old
2. With diagnosed diabetic mellitus (DM), e.g. currently under DM medication treatment or naïve DM subject with duplicated HbA1c over 6.5% and fasting plasma glucose over 126 mg/dL measured at least one week apart before Screening)
3. With at least one cutaneous ulcer on the foot (including ulcers on the lower legs) and not healing for at least 4 weeks. The largest diabetic foot ulcer will be selected as target ulcer. If two or more ulcers have the largest size, the one with worst grade will be selected. If two or more ulcers have the largest size and grade, the one with longest duration will be selected.
4. The target ulcer is classified as grade 1 to 3 ulcer according to Wagner Grading System and with ulcer size of 1 cm2 to 36 cm2 (Grade 3 ulcer subject may enter the study only if after debridement, the abscess of target ulcer is under control at investigator's discretion and osteomyelitis does not present)
5. Diabetic foot ulcers should be free of any necrosis or infection in any soft tissue and bone tissue;
6. Subject has signed the written informed consent form

Exclusion Criteria

1. With active osteomyelitis

2. With target ulcer size decreased by at least 30% after at least 2 weeks of standard-of-care-only period or any other recorded regular therapy either before Screening visit or after completing Initial Phase

3. With poor nutritional status (albumin < 2g/dl), poor diabetic control (HbA1c > 12%), a leukocyte counts < 2,000/mm3, abnormal liver function (AST, ALT>3 x upper limit of normal range) within 14 days before Screening visit or 28 days before Randomization visit Note: HbA1c: hemoglobin A1c; AST: aspartate aminotransferase; ALT: alanine aminotransferase

4. Requiring treatment with systemic corticosteroids, immunosuppressive or chemotherapeutic agents

5. With known or suspected hypersensitivity to any ingredients of study product and vehicle

6. With coronary heart disease with myocardial infarction, coronary artery bypass graft (CABG), or percutaneous transluminal coronary angioplasty (PTCA) within 3 months prior to study

7. Pregnant or lactating or premenopausal with childbearing potential but not taking reliable contraceptive method(s) during the study period Note: Women with childbearing potential should agree to use a highly effective method of birth control, defined as those, alone or in combination, that result in a low failure rate when used consistently and correctly.

8. With the following conditions:

   1. ankle brachial index (ABI) < 0.4 OR
   2. ABI between 0.4 and 0.6 (inclusive) and not received appropriate treatment for improving venous and arterial insufficiency Note: Subjects with ABI between 0.4 and 0.6 (inclusive) and having received appropriate surgical or endovenous/endovascular therapy for improving venous and arterial insufficiency considered by investigators such as valvuloplasty, angioplasty, or bypass grafting will be eligible to enter the study at investigator's discretion.

9. Enrollment in any investigational drug trial within 4 weeks before entering this study

10. With any condition judged by the investigator that entering the trial may be detrimental to the subject

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
ENERGI-F703	ENERGI-F703	ENERGI-F703, topical application, 2 times daily for 12 weeks
Placebo	ENERGI-F703 matched vehicle	ENERGI-F703 matched vehicle, topical application, 2 times daily for 12 weeks

Primary Outcome Measures

Name	Time	Method
The ulcer closure rate	Week 12	Defined as the proportion of subjects with complete ulcer closure at the end of treatment period

Secondary Outcome Measures

Name	Time	Method
The accumulated confirmed ulcer closure rate at each of the post-treatment visit	Week 1, 2, 4 ,6 ,8, 10, 12
The ulcer closure time	Week 1, 2, 4, 6, 8, 10, 12	Defined as the time to complete ulcer closure
Percentage change in ulcer size for each post-treatment visit	Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24	Calculated as (Ulcer size at post treatment visit - Ulcer size at baseline)/(Ulcer size at baseline)
Adverse event incidence	Week 1, 2, 4, 6, 8, 10, 12, 14, 16, 20, 24

Trial Locations

Locations (1)

Tri-Service General Hospital; 🇨🇳 Taipei, Taiwan